The Pharma & Biotech Patent Litigation Summit, Europe 2024

Reviewing First UPC Decisions and their Impact on In-House Patent Litigation Strategy, Join Europe’s Leading Pharmaceutical and Biotech Legal Community to Define, Shape and Create Successful Patent Strategies and Mitigate Risks

Download our 2023 agenda
Amsterdam Central
24-25 January, 2024

“With an ever-changing IP landscape and the imminent arrival of the UPC, now is the time to join the Pharma and Biotech Patent Litigation summit.”

Fred Grumitt, Event Director

Why Attend

The European Summit on Pharma and Biotech Patent Litigation will be back in January 2024 for 3 days of practical discussion around the leading industry topics. Our internationally recognised summit will provide you with the necessary practical tools to both defend patent litigation challenges for your pharma and biotech product, whilst also maximising your litigation strategy to allow for successful IP protection.   

At this event, you will network with leading figures in the industry and gain unique insights on the latest regulatory changes and case-law updates. This makes it a must-attend event for anyone working within the life sciences IP industry. 

2023 Highlights Included

  • The impact of the SPC Referral Cases and the uptake of the Manufacturing Waiver with Heidi Adler (Orion Corporation), James Horgan (MSD) and Robin Ellis (Reddie & Grose).
  • Transatlantic understanding of Biologics Patent Litigation with topics such as: biosimilar launches, section 112 and sufficiency of disclosure with Julia Pike (Sandoz), Mike Cottler (Alvotech) and Robert Cerwinski (Gemini Law). 
  • Examine recent case law in Europe on preliminary injunctions and assess how the decisions affect your litigation strategy with Jenny Davies (Gowling WLG), Peter Meier-Beck (UPC Advisory Committee), Sara Burghart (Sandoz), and Gerben Hartman (CJEU).

2023 Dedicated UPC Sessions

  • Action-packed pre-event workshop day, including UPC Mock Trial with our chair, Peter Meier-Beck (UPC Advisory Committee).
  • Patent Litigation Strategies at the UPC covering Pharma and Biotech approaches to the court, technical changes, and operational challenges with Fiona Bor (Mereo BiopPharma), Stefan Luginbuehl (EPO), Gabriel Cuonzo (Trevisan & Cuonzo), and Kristin Cooklin (Zentiva).
  • UPC Regulatory Update: Advisory Committee and Board of Appeal, with an exploration of the best venues for litigation at the UPC, procedure for the selection of the judges, and insights on all the latest developments regarding UPC procedure with Willem Hoyng (UPC Advisory Committee Chairman), and Peter Blok, (Judge, UPC Court of Appeals).
  • UPC Judicial Panel Session with UPC Judges András Kupecz, Paolo Gerli, and Margot Kokke.

Life Sciences Patent Advisory Board

Author:

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz

Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz

Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.

Author:

Christof Bull

Assistant General Patent Counsel
UCB

Christof Bull

Assistant General Patent Counsel
UCB

Author:

Karine Crepin

Global Head Vaccines Patents
GSK

Karine Crepin is the Vice President, Head of Vaccines Patents at GSK. She holds a Master Degree in Bioengineering (specialising in Biochemistry) and a PhD in molecular Biology. She is also a qualified European and Belgian Patent Attorney.

Before re-joining GSK in her current role, she worked for more than 9 years at Sanofi where she built a global team of more than 40 patent attorneys worldwide responsible for all patent matters relating to Sanofi Biologics including Vaccines and platform aspects, and before that for 15 years at GSK vaccines where she started her patent career.

Karine coordinates a large variety of patent related activities, from the protection of innovation to freedom-to-operate and post-grant administrative and judicial proceedings.

Karine Crepin

Global Head Vaccines Patents
GSK

Karine Crepin is the Vice President, Head of Vaccines Patents at GSK. She holds a Master Degree in Bioengineering (specialising in Biochemistry) and a PhD in molecular Biology. She is also a qualified European and Belgian Patent Attorney.

Before re-joining GSK in her current role, she worked for more than 9 years at Sanofi where she built a global team of more than 40 patent attorneys worldwide responsible for all patent matters relating to Sanofi Biologics including Vaccines and platform aspects, and before that for 15 years at GSK vaccines where she started her patent career.

Karine coordinates a large variety of patent related activities, from the protection of innovation to freedom-to-operate and post-grant administrative and judicial proceedings.

Author:

Fredrik Fredh

European Patent Attorney
Chr. Hansen

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Fredrik Fredh

European Patent Attorney
Chr. Hansen

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Author:

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

Author:

Mathilde Rauline

Head of Greater Europe Patent Litigation
Sanofi

Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.

She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).

She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.

Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.

Mathilde Rauline

Head of Greater Europe Patent Litigation
Sanofi

Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.

She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).

She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.

Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.

Author:

Lorenz Kallenbach

Senior Corporate Patent Counsel
Merck

Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.

Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.

Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.

Lorenz Kallenbach

Senior Corporate Patent Counsel
Merck

Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.

Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.

Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.

Author:

Stephan Kutik

Director, Intellectual Property
Genevant Sciences GmbH

Stephan Kutik

Director, Intellectual Property
Genevant Sciences GmbH

Author:

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

Author:

Mike Cottler

Global Head of Litigation
Alvotech

Mike Cottler

Global Head of Litigation
Alvotech
150+
Attendees
30+
Leading Top Speakers
10+
Jurisdiction-specific Roundtable Discussions

Download Agenda for 2023

Download the 2023 agenda of our upcoming event to get a preview of our key sessions, newly confirmed advisory board members, industry-leading partners and all the compelling facets of the programme.

 

Download Full Agenda

Portfolio Testimonials

Partner With Us

Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

To discuss your objectives and partnership opportunities please contact [email protected]

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]

Resources

Download Resource

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us